EME Equity Market – March 2026 All indices decline, with Greek ASE posting the steepest loss. The MSCI EM Europe Index fell 8.0% mom in EUR terms and 10.8% mom in USD terms in March. The Greek ASE was the worst performer (-9.3% mom); followed by the Czech PX (-6.7% mom); the Hungarian BUX (-6.2% mom); the Turkish ISE30 (-5.1% mom); and the Polish WIG20 (-4.5% mom; all in EUR terms). The Romanian BET proved the most resilient, declining just 1.2% mom, in EUR terms.
A director at Synektik SA bought 382 shares at 262.400PLN and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
HEADLINES: • Synektik: healthcare play, with multiple tailwinds (BUY - initiation of coverage) • EEMEA macro: early takes on the Iran conflict • Cyfrowy Polsat/Wirtualna Polska: CPS audience share at 21.21%, while WP TV at 0.51% in February 2026 NEUTRAL • Primoco UAV: EUR 4m order for Spanish Guardia Civil POSITIVE • Richter: acquires WHC discovery portfolio of Celmatix NEUTRAL • Banca Transilvania: 2026E guidance NEUTRAL • Premier Energy: acquisition of six minority stakes and sale of stake in ...
We initiate coverage of Synektik, which distributes and services medical equipment, and manufactures radiopharmaceuticals, with a BUY and a price target (PT) of PLN 357/share. We see a strong demographic tailwind for the business, as well mid- and long-term demand for replacement systems, including its main product, Intuitive’s Da Vinci surgical robots. The FY25E results should be extraordinarily strong, but Synektik should still generate a mid-teens FY24-FY27E earnings CAGR, with upside, should...
A director at Voxel S.A. sold 2,000 shares at 52.609PLN and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.